Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 63.07 +1.95 (3.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $61.12 | 52 Week High | $77.12 | |||
| Open | $61.46 | 52 Week Low | $49.03 | |||
| Day High | $63.16 | P/E | 40.95 | |||
| Day Low | $61.04 | EPS | $1.54 | |||
| Volume | 4,869,118 | |||||
| FIVE PRIME THER (NASDAQ: FPRX) | Delayed: 38.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.00 | 52 Week High | $57.79 | |||
| Open | $43.46 | 52 Week Low | $28.01 | |||
| Day High | $38.00 | P/E | N/A | |||
| Day Low | $38.00 | EPS | $-2.50 | |||
| Volume | 329,789 | |||||
